series-b
Stage
1
Investors
About
TigaTx develops engineered immunoglobulin A (IgA) antibodies designed to engage neutrophils and harness their tumor-killing potential as a novel therapeutic approach for cancer immunotherapy.
Explore TigaTx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.